Advertisement
UK markets closed

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • CRUDE OIL

    82.76
    -0.60 (-0.72%)
     

  • GOLD FUTURES

    2,329.10
    -13.00 (-0.56%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,318.33
    -1,861.79 (-3.50%)
     

  • CMC Crypto 200

    1,378.56
    -45.54 (-3.20%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

GSK Ebola vaccine fast-tracked into U.S., UK and African trials

Reuters - UK Focus

LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline (Other OTC: GLAXF - news) is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.

Britain's biggest drugmaker said on Thursday the research was being accelerated with funding from an international consortium, reflecting mounting concern over the worst-ever outbreak of the disease in West Africa that has killed more than 1,500 people.

The candidate vaccine, which is being co-developed with the U.S. National Institutes of Health (NIH), is expected to be given to healthy volunteers in Britain and the United States from around mid-September, with the programme then being extended to volunteers in Gambia and Mali.

(Reporting by Ben Hirschler, Editing by Paul Sandle)